吉西他滨联合卡培他滨治疗复发或转移性乳腺癌36例的疗效观察  

Efficacy and Observation of Gemcitabine Combined with Capecitabine for 36 Patients of Recurrent Metastatic Breast Cancer

作　　者：莫军扬[1] 张敏敏[1] 覃舒婷[1] 

机构地区：[1]广西医科大学第五附属医院乳腺外科,545006

出　　处：《实用癌症杂志》2013年第3期249-252,共4页The Practical Journal of Cancer

基　　金：广西卫生厅科技攻关项目(合同号:Z2007305)

摘　　要：目的探讨吉西他滨联合卡培他滨治疗复发或转移性乳腺癌的疗效与毒副作用。方法对符合标准的36例转移性乳腺癌患者给予吉西他滨联合卡培他滨方案治疗,吉西他滨1 000 mg/m2静脉滴注30 min,第1,8天;卡培他滨2 500 mg/m2口服,每天2次,第1～14天,休息1周,每3周重复1次。治疗2个周期以上,对其有效率及不良反应进行评估。结果全组36例共完成148个周期的治疗,中位数4周期,均可评价疗效。有效率(RR)为58.3%,其中CR3例,PR 18例,SD 8例,PD 7例。不良反应主要为骨髓抑制、胃肠道反应及手足综合征(HFS),部分患者出现肝、肾功能损害。结论吉西他滨联合卡培他滨治疗复发转移性乳腺癌患者有一定的疗效,其毒副作用患者可以耐受。Objective To evaluate the efficacy and toxicities of Gemcitabine combined with Capecitabine for recurrent metastatic breast cancer.Methods 36 patients received 30-minute intravenous injection of gemcitabine（1000 mg/m2） on Days 1 and 8;and took Capecitabine orally,2500 mg/m2/d,twice daily for 2 weeks followed by a 1-week rest,repeated every 3 weeks.All enrolled patients received at least 2 cycles of treatment.Results Overall 148 cycles were given to the 36 patients（median,4 cycles）enrolled into the study.All can be evaluated.The response rate was 58.3%,3 patients achieved complete response（CR）,18 patients achieved partial remission（PR）,8 patients achieved stable disease（SD）,7 patients achieved progressive disease（PD）.The major side effects were bone marrow suppression,gastrointestinal effects and hand-foot syndrome（HFS）.Some patients had hepar and renal functional lesion.Conclusion The combination of Gemcitabine and Capecitabine is an efective and well tolerated regimen for the patients with recurrent metastatic breast cancer.

关 键 词：乳腺癌 吉西他滨 卡培他滨 毒副作用 

分 类 号：R737.9[医药卫生—肿瘤]